Direct evidence to support the role of antigen-specific CD8(+) T cells in melanoma-associated vitiligo.

Vitiligo is a cutaneous pigmentary disorder characterized by the loss of melanocytes. An autoimmune mechanism is strongly suspected to be involved in this affection given that it is frequently associated with autoimmune hormonal disorders, and because antibodies directed against melanocytic antigens are found in the serum of patients with vitiligo. We examined the role of cellular immunity in melanoma-associated vitiligo by expanding infiltrating lymphocytes from fresh biopsy specimens of vitiligo patches in melanoma patients. The vitiligo-infiltrating lymphocytes were almost exclusively T lymphocytes, and most were CD8(+). Following in vitro expansion, vitiligo-infiltrating lymphocytes remained predominantly CD8(+) and expressed the cutaneous homing receptor CLA. Furthermore, vitiligo-infiltrating lymphocytes had a clonal or oligoclonal T cell receptor profile, possibly reflecting specific antigenic stimulation. Finally, vitiligo- infiltrating lymphocytes specifically recognized differentiation antigens shared by normal melanocytes and melanoma cells. This direct demonstration of CD8(+) T cell involvement in vitiligo suggests that, in melanoma patients, vitiligo may be a visible effect of a spontaneous antitumoral immune response.

[1]  D. Speiser,et al.  Ex Vivo IFN-γ Secretion by Circulating CD8 T Lymphocytes: Implications of a Novel Approach for T Cell Monitoring in Infectious and Malignant Diseases1 , 2001, The Journal of Immunology.

[2]  Mark M. Davis,et al.  Melanocyte Destruction after Antigen-Specific Immunotherapy of Melanoma , 2000, The Journal of experimental medicine.

[3]  D. Strunk,et al.  Adoptive transfer of vitiligo after allogeneic bone marrow transplantation for non-Hodgkin's lymphoma , 2000, The Lancet.

[4]  D. Speiser,et al.  Cutting Edge: Cytolytic Effector Function in Human Circulating CD8+ T Cells Closely Correlates with CD56 Surface Expression1 , 2000, The Journal of Immunology.

[5]  J. Becker,et al.  Accumulation of identical T cells in melanoma and vitiligo-like leukoderma. , 1999, The Journal of investigative dermatology.

[6]  O. Lantz,et al.  Persistent alterations in T-cell repertoire, cytokine and chemokine receptor gene expression after 1 year of highly active antiretroviral therapy. , 1999, AIDS.

[7]  A. Sette,et al.  Identification of GP100‐derived, melanoma‐specific cytotoxic T‐lymphocyte epitopes restricted by HLA‐A3 supertype molecules by primary in vitro immunization with peptide‐pulsed dendritic cells , 1998, International journal of cancer.

[8]  G. Ogg,et al.  High Frequency of Skin-homing Melanocyte-specific Cytotoxic T Lymphocytes in Autoimmune Vitiligo , 1998, The Journal of experimental medicine.

[9]  J. Shabanowitz,et al.  Human melanoma patients recognize an HLA-A1-restricted CTL epitope from tyrosinase containing two cysteine residues: implications for tumor vaccine development. , 1998, Journal of immunology.

[10]  P. Romero,et al.  Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. , 1998, Journal of immunology.

[11]  C. Bunce,et al.  CD4+ T-cell memory, CD45R subsets and the persistence of antigen--a unifying concept. , 1998, Immunology today.

[12]  S. Serrano‐Ortega,et al.  Vitiligo-like lesions in patients with melanoma treated with immunotherapy , 1997 .

[13]  J. Kieffer,et al.  Cutaneous lymphocyte antigen is a specialized form of PSGL-1 expressed on skin-homing T cells , 1997, Nature.

[14]  P. Walker,et al.  TCR analysis reveals significant repertoire selection during in vitro lymphocyte culture. , 1997, International immunology.

[15]  D. Hunt,et al.  Shared epitopes for HLA-A3-restricted melanoma-reactive human CTL include a naturally processed epitope from Pmel-17/gp100. , 1996, Journal of immunology.

[16]  L. Dubertret,et al.  More on cutaneous reactions to recombinant cytokine therapy. , 1996, Journal of the American Academy of Dermatology.

[17]  A Sette,et al.  Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. , 1996, Journal of immunology.

[18]  P. Fishman,et al.  Tyrosinase as an autoantigen in patients with vitiligo , 1996, Clinical and experimental immunology.

[19]  P. Fishman,et al.  Anti-tyrosinase antibodies in malignant melanoma , 1996, Cancer Immunology, Immunotherapy.

[20]  W. Westerhof,et al.  Presence of T cells and macrophages in inflammatory vitiligo skin parallels melanocyte disappearance. , 1996, The American journal of pathology.

[21]  J. Shabanowitz,et al.  An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins , 1996, The Journal of experimental medicine.

[22]  T. Boon,et al.  A tyrosinase nonapeptide presented by HLA‐B44 is recognized on a human melanoma by autologous cytolytic T lymphocytes , 1996, European journal of immunology.

[23]  J. Guillet,et al.  Preferential usage of the T-cell receptor by influenza virus hemagglutinin-specific human CD4+ T lymphocytes: in vitro life span of clonotypic T cells , 1995, Journal of virology.

[24]  K. Sakaguchi,et al.  Identification of a tyrosinase epitope recognized by HLA-A24-restricted, tumor-infiltrating lymphocytes. , 1995, Journal of immunology.

[25]  J. Bystryn,et al.  Melanoma and vitiligo are associated with antibody responses to similar antigens on pigment cells. , 1995, Archives of dermatology.

[26]  M. Lotze,et al.  Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes , 1995, The Journal of experimental medicine.

[27]  N. Maclaren,et al.  The role of tyrosinase in autoimmune vitiligo , 1994, The Lancet.

[28]  A. Lanzavecchia,et al.  An invariant V alpha 24-J alpha Q/V beta 11 T cell receptor is expressed in all individuals by clonally expanded CD4-8- T cells , 1994, The Journal of experimental medicine.

[29]  B. Seliger,et al.  Two tyrosinase nonapeptides recognized on HLA‐A2 melanomas by autologous cytolytic T lymphocytes , 1994, European journal of immunology.

[30]  T. Olsson,et al.  Number of interleukin‐4‐ and interferon‐γ‐secreting human T cells reactive with tetanus toxoid and the mycobacterial antigen PPD or phytohemagglutinin: distinct response profiles depending on the type of antigen used for activation , 1993, European journal of immunology.

[31]  J. Garioch,et al.  An immunohistological study of cutaneous lymphocytes in vitiligo , 1993, The Journal of pathology.

[32]  J. Bystryn,et al.  Identification of pigment cell antigens defined by vitiligo antibodies. , 1992, The Journal of investigative dermatology.

[33]  A. Ilchyshyn,et al.  Prolonged survival in metastatic malignant melanoma associated with vitiligo , 1991, Clinical and experimental dermatology.

[34]  A. Kopf,et al.  Prognostic significance of hypopigmentation in malignant melanoma. , 1987, Archives of dermatology.

[35]  P. Chomczyński,et al.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.

[36]  J. Kirkwood,et al.  Vitiligo in patients with metastatic melanoma: a good prognostic sign. , 1983, Journal of the American Academy of Dermatology.

[37]  G. Naughton,et al.  Antibodies to normal human melanocytes in vitiligo , 1983, The Journal of experimental medicine.

[38]  S. Rosenberg,et al.  Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. , 1996, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[39]  J. Nordlund,et al.  Vitiligo: It Is Important , 1982 .